1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Dutch Competition Body Urged To Fine Leadiant Over 'Exorbitant' Orphan Drug Price

 
• By Ian Schofield

The Dutch Pharmaceutical Accountability Foundation has asked the country's competition authority to take action against Leadiant Biosciences over the company's pricing of an orphan drug for a rare genetic disease. 

SC1711_Purse-Pills_673872868_1200
Leadiant is accused of charging too much for its CTX drug

The new Dutch foundation that has criticized the pricing of Leadiant’ Biosciences’ orphan drug CDCA on Sept. 7 will file a formal request with the Dutch competition authority asking it to either fine the company or take some other action over what it calls the “exorbitant price the company is asking.”

Leadiant’s CDCA product, which has EU approval for the treatment of the rare genetic disease cerebrotendinous xanthomatosis (CTX), is currently...

Welcome to Pink Sheet

Create an account to read this article

Already a subscriber?

More from Pricing Debate

Pharma Cooperating With Trump On Direct Sale To Consumers, Pfizer CEO Says

 
• By Jessica Merrill

Pfizer is in active discussions with Trump on MFN pricing and collaborating with peers on direct sales as an approach to lower drug prices, CEO Albert Bourla said.

Cuban: Drugmakers Are More Afraid of PBMs Than Trump

 
• By Leslie Small

The billionaire investor said during a recent conference that brand drug manufacturers want to work with his Cost Plus Drug Co., but are afraid the PBMs will retaliate.

Most Favored Nation Pricing: Trump Ups Pressure On Voluntary Action, Clarifies Demands

 
• By Sarah Karlin-Smith

The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.

340B Rebate Model Gets HRSA Endorsement; Pilot Program Limited To Medicare Negotiated Drugs

 
• By Cathy Kelly

Pilot is harbinger of greater transparency in the 340B program. But rebates may only be denied by manufacturers for overlap with Medicare negotiated prices, not for issues like diversion that have driven recent lawsuits.

More from Market Access

Faster HTA Reviews & Pricing Reform Could Help Fix Canada’s Drug Access Woes

 
• By Eliza Slawther

Canadian politicians must “move quickly” to introduce policies that will speed up access to medicines, such as by broadening criteria for the temporary reimbursement of medicines, the Canadian Chamber of Commerce says.

Most Favored Nation Pricing: Trump Ups Pressure On Voluntary Action, Clarifies Demands

 
• By Sarah Karlin-Smith

The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.

340B Rebate Model Gets HRSA Endorsement; Pilot Program Limited To Medicare Negotiated Drugs

 
• By Cathy Kelly

Pilot is harbinger of greater transparency in the 340B program. But rebates may only be denied by manufacturers for overlap with Medicare negotiated prices, not for issues like diversion that have driven recent lawsuits.